Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 9 | -$0.61 | -$0.49 | -$0.56 |
| Q2 2026 | 9 | -$0.62 | -$0.48 | -$0.56 |
| Q3 2026 | 3 | -$0.60 | -$0.60 | -$0.60 |
| Q4 2026 | 7 | -$0.59 | -$0.59 | -$0.59 |
| Q1 2027 | 3 | -$0.62 | -$0.62 | -$0.62 |
| Q2 2027 | 3 | -$0.58 | -$0.58 | -$0.58 |
| Q3 2027 | 4 | -$0.54 | -$0.54 | -$0.54 |
| Q4 2027 | 3 | -$0.51 | -$0.51 | -$0.51 |
Immunome Inc last posted its earnings results on Tuesday, May 12th, 2026. The company reported $-0.48 earnings per share for the quarter, topping analysts' consensus estimates of $-0.6 by $0.12. The company had revenue of 0 for the quarter and had revenue of 6.94 M for the year. Immunome Inc has generated $-2 earnings per share over the last year ($-2.43 diluted earnings per share) and currently has a price-to-earnings ratio of -11.18. Immunome Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/12/2026 | Q1 2026 | -$0.60 | -$0.48 | 0.12 | $222.22 K | $0 |
| 03/03/2026 | Q4 2025 | -$0.59 | -$0.76 | -0.17 | $876.03 K | $0 |
| 11/06/2025 | Q3 2025 | -$0.57 | -$0.65 | -0.08 | $800.00 K | $0 |
| 08/06/2025 | Q2 2025 | -$0.52 | -$0.50 | 0.02 | $833.33 K | $4.02 M |
| 05/12/2025 | Q1 2025 | -$0.66 | -$0.52 | 0.14 | $783.27 K | $2.93 M |
| 03/19/2025 | Q4 2024 | -$0.68 | -$1.28 | -0.6 | $3.15 M | $2.74 M |
| 11/13/2024 | Q3 2024 | -$0.60 | -$0.78 | -0.18 | $2.29 M | $2.91 M |
| 08/12/2024 | Q2 2024 | -$0.38 | -$0.60 | -0.22 | $1.87 M | $2.36 M |
| 05/14/2024 | Q1 2024 | -$0.80 | -$12.56 | -11.76 | $2.80 M | $1.03 M |
| 03/28/2024 | Q4 2023 | -$0.28 | -$4.22 | -3.94 | N/A | $3.83 M |
| 11/09/2023 | Q3 2023 | -$0.17 | -$0.36 | -0.19 | N/A | $3.57 M |
| 08/09/2023 | Q2 2023 | -$0.16 | -$0.46 | -0.3 | N/A | $4.26 M |
| 05/05/2023 | Q1 2023 | $0.59 | -$0.33 | -0.92 | N/A | $2.36 M |
| 03/16/2023 | Q4 2022 | $0.67 | -$0.69 | -1.36 | N/A | $0 |
| 11/14/2022 | Q3 2022 | -$0.76 | -$0.70 | 0.06 | N/A | $0 |
| 08/05/2022 | Q2 2022 | -$0.75 | -$0.74 | 0.01 | N/A | $0 |
| 05/12/2022 | Q1 2022 | -$0.69 | -$0.96 | -0.27 | N/A | $0 |
| 03/28/2022 | Q4 2021 | -$0.81 | -$0.66 | 0.15 | N/A | $0 |
| 11/15/2021 | Q3 2021 | -$0.50 | -$0.65 | -0.15 | N/A | $0 |
| 08/16/2021 | Q2 2021 | -$0.39 | -$0.46 | -0.07 | N/A | $0 |
In the previous quarter, Immunome Inc (:IMNM) reported $-0.48 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.6 by $0.12.
The conference call for Immunome Inc's latest earnings report can be listened to online.
The conference call transcript for Immunome Inc's latest earnings report can be read online.
Immunome Inc (:IMNM) has a recorded annual revenue of $6.94 M.
Immunome Inc (:IMNM) has a recorded net income of $-212,394,000.Immunome Inc has generated $-2.43 earnings per share over the last four quarters.
Immunome Inc (:IMNM) has a price-to-earnings ratio of -11.18 and price/earnings-to-growth ratio is -0.39.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED